BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Resonance Health Limited (RHT.AX) Receives FDA Approval for MRI-Q Cardiac Iron T2* Test


8/16/2011 6:43:01 AM

SAN DIEGO--(BUSINESS WIRE)-- Resonance Health Ltd, a medical device company specializing in imaging core laboratory services has received FDA clearance to market its MRI-Q System. The test measures cardiac T2* which is a highly sensitive surrogate marker for cardiac iron.

Resonance Health’s other product on market is FerriScan® R2-MRI (www.ferriscan.com), which provides an accurate assessment of liver iron concentration (LIC). The MRI-Q system provides an opportunity to broaden the Company’s range of solutions to address the iron overload market.

Iron overload can occur in patients who are dependent on blood transfusions for the treatment of conditions such as thalassemia, sickle cell disease and myelodysplastic syndrome. It can also be caused by excessive dietary absorption of iron through hereditary hemochromatosis, one of the most common genetic disorders in the United States. Iron overload can result in organ damage and the accumulation of cardiac iron is the leading cause of death in patients with ß-thalassemia major.

FerriScan R2-MRI and now the MRI-Q system are provided to the market as a combined service for both the liver and cardiac T2* iron assessment. To access FerriScan R2-MRI and MRI-Q, an MRI center transmits image data electronically via a secure internet portal to the Company’s quality-controlled, ISO9001 certified central core lab where experts conduct the analysis. Resonance Health can now provide clinicians with added value by including both liver iron and cardiac T2* results in the data analysis.

“Customers can start using the service immediately,” said Liza Dunne, Managing Director. “There are no additional software or hardware purchases needed and the price of MRI-Q and FerriScan R2-MRI is charged on a “per-scan” basis. FerriScan R2-MRI is currently used by global pharmaceutical companies in multicenter clinical trials for iron chelation therapy products and by several hospitals in the United States. Cardiac iron assessments will be delivered with the same standards of quality and consistency that clinicians have come to expect from FerriScan R2-MRI.”

Resonance Health is also developing technology for the quantitative MRI-based measurement of fatty liver and liver fibrosis and welcomes collaborations in these fields.

Contact:

Resonance Health LtdU.S. Contact:Noreen J. Sullivan, Vice Presidentnoreens@resonancehealth.com Toll-Free: (877) 635-3724 www.resonancehealth.com Corporate:Liza Dunne, Managing Directorlizad@resonancehealth.com Tel: +61 (8) 9286 5300



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES